The Strategic Evolution of Biosimilars in the MENA Region: A New Era for Chronic Disease Management

The healthcare landscape of the Middle East and North Africa (MENA) is currently undergoing a seismic shift. As the region grapples with an aging population and a significant surge in non-communicable diseases (NCDs), the demand for advanced therapeutic interventions has never been higher. At the heart of this transformation lies the rapid growth of biosimilars, biological medicinal products that are highly similar to already approved reference biologics. Unlike traditional generics, biosimilars offer a sophisticated solution to managing complex chronic conditions such as diabetes, oncology, and autoimmune disorders, while simultaneously addressing the economic pressures faced by national healthcare budgets.

According to the World Health Organization (WHO), non-communicable diseases are now responsible for nearly 74% of all deaths globally, with a disproportionately high impact in the Eastern Mediterranean region, where chronic conditions account for over 2.8 million deaths annually. This clinical burden has forced MENA governments to look beyond traditional pharmaceutical models toward sustainable, high-tech alternatives. The integration of biosimilars into national health strategies is no longer just an option; it has become a cornerstone of public health policy across the Gulf Cooperation Council (GCC) and North Africa.

The Rising Burden of Chronic Diseases in the MENA Region

To understand the trajectory of biosimilars, one must first look at the epidemiological data provided by the Centers for Disease Control and Prevention (CDC) and the WHO regarding the region’s health profile. The MENA region currently experiences some of the highest rates of metabolic and cardiovascular diseases in the world. The CDC highlights that chronic diseases, particularly heart disease and stroke, are becoming the leading causes of disability-adjusted life years (DALYs) in the region.

In particular, the prevalence of Type 2 diabetes in countries like Saudi Arabia, the United Arab Emirates, and Kuwait is among the highest globally. The WHO Eastern Mediterranean Regional Office (EMRO) reports that the prevalence of diabetes in the region has reached approximately 14%, a figure that is expected to rise sharply by 2045 if current lifestyle trends persist. For patients with advanced diabetes, biological therapies like insulin glargine are essential. However, the high cost of reference biologics often limits patient access. This is where biosimilars enter the fray, providing identical therapeutic outcomes at a fraction of the cost, thereby allowing ministries of health to expand coverage to a larger segment of the population.

Beyond metabolic health, the oncology sector is witnessing a similar trend. Cancer remains a leading cause of mortality in the MENA region. The WHO’s International Agency for Research on Cancer (IARC) suggests that the cancer burden in the Eastern Mediterranean is set to double by 2040 due to population growth and aging. The treatment of various cancers, including breast and colorectal cancer, increasingly relies on monoclonal antibodies (mAbs). As the patents for these high-cost biologics expire, MENA governments are aggressively fast-tracking the registration of biosimilar versions to ensure that life-saving treatments remain financially viable for national insurance schemes.

Economic Imperatives and Government Initiatives

The primary driver for the adoption of biosimilars in the MENA region is economic sustainability. For years, biological drugs have consumed a disproportionate share of healthcare spending. In the United Arab Emirates, the Ministry of Health and Prevention (MOHAP) has recognized that the high cost of specialty medicines for chronic diseases could jeopardize the long-term goals of the National Strategy for Wellbeing 2031. To mitigate this, the UAE government has implemented policies that encourage the use of biosimilars in public hospitals and through the “Thiqa” and “Saada” health insurance programs.

Similarly, the Kingdom of Saudi Arabia, through its Vision 2030, is focused on the localization of pharmaceutical manufacturing. The Saudi Food and Drug Authority (SFDA) has been a pioneer in the region by establishing a clear and rigorous regulatory pathway for biosimilar approval. The SFDA’s guidelines for biosimilars are closely aligned with those of the European Medicines Agency (EMA) and the WHO, ensuring that any biosimilar entering the Saudi market meets the highest standards of safety, quality, and efficacy. By fostering a competitive market for biosimilars, the Saudi government aims to reduce its healthcare expenditure on biologics, which currently accounts for a significant portion of the Ministry of Health’s pharmaceutical budget.

In North Africa, Egypt has emerged as a major player in the biosimilar space. The Egyptian Drug Authority (EDA) has prioritized the domestic production of biosimilars to support the “100 Million Healthy Lives” initiative. This massive public health campaign, which originally focused on Hepatitis C, has expanded to cover chronic diseases like hypertension and diabetes. The EDA has streamlined the registration process for locally manufactured biosimilars to ensure that the Egyptian population has access to affordable treatments for chronic conditions, reducing the reliance on expensive imports.

Regulatory Frameworks: Ensuring Quality and Safety

One of the most significant hurdles in the growth of biosimilars has been the perception of “similarity.” Unlike generic drugs, which are exact chemical copies of small-molecule drugs, biosimilars are produced in living cells, making them impossible to replicate perfectly. Therefore, regulatory bodies in the MENA region have had to develop sophisticated frameworks to evaluate “analytical biosimilarity.”

The WHO provides the global standard for this evaluation through its “Guidelines on the Evaluation of Similar Biotherapeutic Products (SBPs).” These guidelines emphasize that biosimilars must undergo comparative clinical trials to prove that there are no clinically meaningful differences in terms of safety and potency compared to the reference product. Most MENA countries have adopted these WHO standards. For instance, the Jordanian Food and Drug Administration (JFDA) requires extensive data on the molecular structure, biological activity, and clinical performance of biosimilars before they can be marketed for chronic disease management.

The rigor of these regulations has helped build trust among healthcare providers. In the past, physicians were hesitant to switch patients from a reference biologic to a biosimilar, fearing a loss of efficacy or an adverse immune response. However, the transparent data provided by government bodies like the SFDA and MOHAP has demonstrated that biosimilars are just as effective as their originators. This “regulatory confidence” is a key factor driving the year-on-year growth of biosimilar prescriptions in the region.

Impact on Specific Chronic Diseases

Oncology and Hematology

In the MENA region, the oncology sector has seen the most rapid uptake of biosimilars. Monoclonal antibodies such as Rituximab and Trastuzumab are essential for treating lymphomas and breast cancer. The high price points of the original brands often meant that patients in lower-income MENA countries had limited access. However, the introduction of biosimilars has democratized cancer care. In Morocco, the Ministry of Health has integrated biosimilars into the national oncology program, leading to a significant increase in the number of patients receiving targeted therapies.

Rheumatology and Immunology

Autoimmune diseases such as rheumatoid arthritis and psoriasis require long-term treatment with biologics like Adalimumab and Etanercept. These are chronic, lifelong conditions that can lead to severe disability if not managed properly. The CDC notes that the prevalence of autoimmune conditions is rising globally, and the MENA region is no exception. By switching to biosimilars, MENA health systems have been able to provide these treatments earlier in the disease progression, preventing long-term joint damage and improving the quality of life for thousands of patients.

Endocrinology and Diabetes

As mentioned previously, the diabetes crisis in the MENA region is a primary driver of pharmaceutical demand. The WHO reports that access to affordable insulin is a major challenge in many parts of the world. The growth of biosimilar insulins in the MENA region is directly addressing this gap. Governments in Kuwait and Qatar have utilized their central procurement systems to negotiate lower prices for biosimilar insulins, ensuring that no citizen is left without the medication required to manage their blood glucose levels.

Rare Diseases and Orphan Conditions

Rare diseases, although individually uncommon, collectively impose a significant healthcare burden across the MENA region, particularly due to limited treatment options and the high cost of orphan biologics. Conditions such as Gaucher disease, Fabry disease, and certain rare hematological disorders often rely on enzyme replacement therapies or specialized biologics that are financially out of reach for many patients. The introduction of biosimilars in this space, though still emerging, holds transformative potential. Countries like Saudi Arabia and the UAE are increasingly incorporating biosimilars into national rare disease frameworks to improve accessibility and reduce dependency on high-cost imports. By enabling earlier and sustained treatment, biosimilars can help prevent disease progression, reduce morbidity, and enhance patient survival in populations that were previously underserved due to economic and infrastructural barriers.

Local Manufacturing and Self-Sufficiency

A unique aspect of the MENA biosimilar market is the push for local manufacturing. Governments are moving away from being mere consumers of pharmaceuticals to becoming producers. This shift is driven by a desire for “health security”—ensuring that the supply of essential medicines for chronic diseases is not disrupted by global supply chain issues.

The UAE has positioned itself as a hub for pharmaceutical innovation. Through the Dubai Science Park and the Abu Dhabi Department of Health, the UAE is attracting significant investment in biotech facilities. The Ministry of Industry and Advanced Technology (MoIAT) has introduced incentives for companies to develop biosimilars locally, aligning with the “Operation 300bn” strategy to increase the industrial sector’s contribution to the GDP.

Saudi Arabia is following a similar path. The Saudi Ministry of Investment (MISA) has identified the pharmaceutical and biotech sectors as priority areas. By manufacturing biosimilars domestically, the Kingdom not only reduces its import bill but also creates high-value jobs for its citizens in the science and technology sectors. The SFDA provides technical support to local manufacturers to ensure that their facilities meet Good Manufacturing Practice (GMP) standards, which are essential for producing complex biological products.

Strengthening Pharmacovigilance: Ensuring Long-Term Safety in Biosimilar Use

As the MENA region accelerates the adoption of biosimilars for chronic disease management, the emphasis on pharmacovigilance, the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects, has become paramount. Unlike small-molecule generics, biological products possess an inherent complexity and potential for immunogenicity, where the body’s immune system might respond to the medicine. Consequently, government bodies across the region have established robust post-market surveillance systems to monitor these products throughout their lifecycle.

The Saudi Food and Drug Authority (SFDA) has been a leader in this domain, implementing the “Saudi Vigilance” system. This platform requires healthcare providers and manufacturers to report any adverse drug reactions (ADRs) specifically associated with biological products, ensuring that any rare side effects are identified quickly. The SFDA’s guidelines emphasize the importance of “traceability,” ensuring that the specific brand and lot number of a biosimilar are recorded in the patient’s medical history. This level of detail is critical for distinguishing between the effects of a reference biologic and its biosimilar counterpart.

The World Health Organization (WHO) supports these regional efforts through its “Program for International Drug Monitoring.” The WHO emphasizes that for biosimilars, pharmacovigilance should not only be reactive but also proactive, involving periodic safety update reports (PSURs) that provide a comprehensive picture of the drug’s safety profile as it is used in larger, more diverse populations. By adhering to these global standards, MENA governments are building a foundation of data that reassures both clinicians and patients that biosimilars are being monitored with the highest level of scrutiny.

Biosimilars as a Catalyst for Universal Health Coverage (UHC)

The growth of biosimilars is inextricably linked to the region’s pursuit of Universal Health Coverage (UHC). The WHO defines UHC as ensuring that all people have access to the full range of quality health services they need, when and where they need them, without financial hardship. In many MENA countries, the high cost of biological therapies for chronic diseases has historically been a barrier to achieving this goal.

In the United Arab Emirates, the government’s commitment to UHC is reflected in its “Vision 2021” and the subsequent “Principles of the 50,” which prioritize the health and well-being of all residents. By integrating biosimilars into the national formulary, the UAE Ministry of Health and Prevention (MOHAP) has been able to lower the “per-patient” cost of treatment for conditions like rheumatoid arthritis and Crohn’s disease. This fiscal efficiency allows the government to reallocate funds toward preventative care and the expansion of primary healthcare infrastructure.

In North Africa, the Moroccan government has embarked on a landmark reform to generalize social protection, which includes extending mandatory health insurance to millions of previously uncovered citizens. The National Health Insurance Agency (ANAM) in Morocco has recognized that the sustainability of this expansion depends on the use of cost-effective medicines. The adoption of biosimilars for oncology and chronic respiratory diseases is seen as a vital strategy to ensure that the influx of new patients does not overwhelm the national health budget, thereby making UHC a tangible reality rather than just a policy objective.

Navigating the Technical Nuances of Interchangeability and Switching

One of the most complex areas of biosimilar policy in the MENA region involves “interchangeability” and “switching.” Switching refers to the act of a prescriber changing a patient’s medication from a reference biologic to a biosimilar (or vice versa), while interchangeability is a regulatory designation that allows a pharmacist to make this change without prior consent from the doctor. The MENA region is currently seeing a refined approach to these practices, guided by scientific rigor and patient safety.

The CDC notes that for patients with chronic conditions, maintaining stable drug levels and avoiding immunogenic reactions is essential for successful long-term outcomes. Recognizing this, the Gulf Health Council (GHC), which coordinates healthcare policies across the GCC, has been working toward a unified stance on switching. Most MENA regulators currently advocate for “physician-led switching,” where the decision to move a patient to a biosimilar is made based on clinical evidence and the individual patient’s history.

However, as the body of real-world evidence (RWE) grows, some countries are exploring “automatic substitution” for treatment-naïve patients—those who are starting a biological therapy for the first time. The Egyptian Drug Authority (EDA) has been proactive in evaluating the data surrounding “multiple switches” (switching between different biosimilars of the same reference product). By staying aligned with WHO standards, which state that a biosimilar should only be considered interchangeable if it has undergone specific studies to prove that switching does not diminish efficacy, the EDA ensures that Egyptian patients receive consistent therapeutic benefits.

The Role of Medical Education and the “Paradigm Shift” in Clinical Practice

The successful growth of biosimilars in the MENA region is not solely dependent on regulation and manufacturing; it also requires a paradigm shift in how healthcare providers view these products. Historically, there was a “knowledge gap” regarding the manufacturing and approval process of biosimilars. To address this, MENA governments have launched extensive educational initiatives aimed at doctors, pharmacists, and nurses.

The Sultanate of Oman’s Ministry of Health, for instance, has organized several national symposia to educate clinicians on the “totality of evidence” approach used in biosimilar approval. This approach explains that biosimilars are not approved based on large-scale Phase III trials alone, but on a comprehensive package of analytical, functional, and clinical data that proves similarity to the originator.

These educational efforts are crucial for overcoming the “nocebo effect,” where a patient’s lack of trust in a new, cheaper medicine can lead to a perceived lack of efficacy. By training healthcare providers to communicate effectively with patients about the benefits and safety of biosimilars, governments are ensuring higher rates of treatment adherence. The WHO emphasizes that “patient and provider education” is a critical component of any successful biosimilar program, as it fosters the trust necessary for these medicines to reach their full potential in managing chronic diseases.

Digital Health and the Integration of Biosimilar Data

The MENA region is home to some of the world’s most advanced digital health ecosystems, and these platforms are playing a vital role in the management of chronic diseases via biosimilars. In Saudi Arabia, the “Seha” app and the “Wasfaty” electronic prescribing service allow the Ministry of Health to track the utilization of biosimilars in real-time. This digital infrastructure provides invaluable data on patient outcomes, allowing the government to monitor how biosimilars perform across different demographic groups.

In the UAE, the “Malaffi” and “Nabidh” health information exchanges (HIEs) enable a unified electronic medical record for every patient. When a patient with a chronic condition like diabetes is prescribed a biosimilar insulin, this information is instantly accessible to every specialist the patient visits. This connectivity ensures that the transition from a reference biologic to a biosimilar is documented and monitored across the entire continuum of care.

The WHO’s “Global Strategy on Digital Health 2020-2025” highlights how digital tools can improve the safety and efficacy of medicines. By integrating biosimilar tracking into their digital health frameworks, MENA countries are not only improving patient safety but are also generating local real-world evidence. This data can eventually be used to refine national treatment protocols and contribute to the global understanding of biosimilar performance in diverse populations.

Regional Cooperation: The GCC Centralized Registration Path

One of the most significant accelerators for biosimilar growth in the Middle East is the centralized registration process of the Gulf Cooperation Council (GCC). Managed through the Gulf Health Council, this process allows pharmaceutical manufacturers to submit a single application for the registration of a biosimilar across all GCC member states (Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, and Oman).

This centralized approach reduces the administrative burden on both the manufacturers and the national regulators, leading to faster market entry for essential chronic disease treatments. By pooling their technical expertise, the GCC countries can conduct more thorough evaluations of complex biological dossiers. This regional cooperation ensures that even the smaller member states have access to the same high-quality, government-vetted biosimilars as their larger neighbors.

Challenges to Overcome

Despite the promising growth, several challenges remain. The first is “interchangeability”, the practice of a pharmacist switching a patient from a reference biologic to a biosimilar without the intervention of the prescribing physician. While some countries like the United States have specific designations for interchangeability, many MENA countries are still refining their policies on this issue. The WHO suggests that decisions regarding switching should be made by clinical professionals in consultation with patients.

Another challenge is the “nocebo effect,” where patients’ negative expectations about a lower-cost medicine lead to perceived side effects or reduced efficacy. To combat this, MENA governments are investing in medical education. Ministries of health are conducting workshops for doctors and pharmacists to explain the rigorous testing that biosimilars undergo, ensuring that healthcare providers can confidently recommend these treatments to their patients.

Furthermore, the cold-chain logistics required for biological products present a significant hurdle in the MENA region, where temperatures can exceed 50°C. Maintaining the stability of biosimilars from the factory to the patient requires a robust and sophisticated infrastructure. Government investments in specialized logistics hubs, particularly in the UAE’s Jebel Ali Free Zone and Saudi Arabia’s King Abdullah Economic City, are helping to address these logistical challenges.

The Future Outlook

The future of biosimilars in the MENA region is undeniably bright. As more biological patents expire in the coming decade, the market is expected to expand even further. We are likely to see a shift from “simple” biosimilars like insulin to more complex products, including biosimilar versions of orphan drugs for rare chronic diseases.

The WHO’s Global Action Plan for the Prevention and Control of NCDs 2013-2030 highlights the importance of access to essential medicines. Biosimilars are the most viable pathway for MENA countries to achieve the targets set out in this plan. By combining rigorous regulation, support for local manufacturing, and proactive clinical education, the region is setting a global example of how to integrate advanced biotechnology into public health systems.

The transformation we are witnessing is not just about cost-cutting; it is about expanding the horizons of what is possible in chronic disease management. For the millions of people in the MENA region living with diabetes, cancer, or autoimmune disorders, the growth of biosimilars represents a promise of a healthier, more sustainable future.